Abstract Malignant glioma is usually accompanied by vigorous angiogenesis to provide essential nutrients. An effective glioma targeting moiety should include excellent tumor-cell homing ability as well as good neovasculature-targeting efficiency, and should be highly resistant to enzyme degradation in the bloodstream. The phage display-selected heptapeptide, the glioma-initiating cell peptide (GICP), was previously reported as a ligand for the VAV3 protein (a Rho-GTPase guanine nucleotide exchange factor), which is mainly expressed on glioma cells; the stabilized heptapeptide D A7R has been shown to be the ligand of both vascular endothelial growth factor receptor 2 (VEGFR2) and neuropilin-1 (NRP-1), and has demonstrated good neovasculature-targeting ability. By linking D A7R and GICP, a multi-receptor targeting molecule was obtained. The stability of these three peptides was evaluated and their targeting efficiency on tumor-related cells and models was compared. The ability of these peptides to cross the blood-tumor barrier (BTB) was also determined. The results indicate that the coupled Y-shaped peptide D A7R-GICP exhibited improved tumor and neovasculature targeting ability and had higher efficiency in crossing the BTB than either individual peptide.
Introduction
Glioblastoma, the most common and aggressive type of brain tumor, accounts for 29% of all primary brain and central nervous system tumors and 80% of malignant tumors 1, 2 . It is highly fatal with a median survival time of 15 months, with only 10% of patients having a 5-year overall survival [3] [4] [5] . Conventional chemotherapy lacks selectivity after systemic administration, causing severe adverse effects 6, 7 . The current trend to develop gliomatargeting therapeutic strategies can minimize adverse effects, but most approaches focused only on killing tumor cells and decreasing systematic toxicity, ignoring the importance of inhibiting tumor angiogenesis, an essential component of tumor proliferation, evasion, and metastasis [8] [9] [10] . Moreover, the abundant proteases in blood are the first barriers for drug delivery, with the blood-tumor barrier (BTB) the second physiological and enzymatic barrier. The most severe disadvantage of a peptide-based targeting moiety is that it can be degraded by peptidases and proteases in blood, but it has been demonstrated that stabilized peptides can accumulate in tumor tissue to a greater extent than un-stabilized peptides 11 . In addition, because of BTB, circulating targeting molecules need to penetrate the neovasculature made up of vascular endothelia cells to reach the tumor. Therefore, targeting moieties must demonstrate efficient tumor-related cell and blood vessel uptake, as well as protease resistance 12 . In a previous report, VAV3 (a Rho-GTPase guanine nucleotide exchange factor) was shown to be upregulated in glioma cells, and especially glioma stem cells 13 and its expression in U87MG cells was greater than in HUVECs (regarded as tumor related vascular endothelial cells), suggesting that VAV3 could be a potential target for glioma-cell targeting 14 . The heptapeptide GICP (glioma-initiating cell peptide), consisting of all natural L-amino acids, was identified by phage display technique and shown to have a high affinity for the VAV3 protein. Due to its unique amino combination, GICP peptide cannot be optimized by a retro-inverse strategy that utilizes all D-amino acids in reverse sequence (unpublished results) but conjugation with a D-peptide could improve its enzymatic stability 15 . D A7R is a ligand of the vascular endothelial growth factor receptor 2 (VEGFR2) and neuropilin-1 (NRP-1), which is mainly and highly expressed by tumor neovasculature [16] [17] [18] [19] . Since A7R is a C-terminal peptide and the sequence of Pro-Arg plays a vital role in receptor recognition [20] [21] [22] , retro-inversed D A7R peptide was arranged such that the critical amino acids were exposed at the N-terminal when coupled to GICP to yield peptide 19, 23 . In the present work, the stability of the three peptides to enzyme degradation was investigated and their targeting efficiencies were compared in U87MG cells, HUVECs and an ex vivo neovasculature model formed by HUVECs. A lysosome colocalization assay and quantitative measurement of the amount of peptide able to cross the BTB model were also conducted. The results indicated that the new Y-shaped peptide D A7R-GICP exhibited better tumor and neovasculature targeting ability and had higher efficiency for crossing the BTB than GICP or D A7R individually. The D A7R-GICP may be a promising multi-receptor recognition peptide for glioma targeting.
Materials and methods

Materials
Boc-protected α-amino acids were purchased from GL Biochem Ltd. (Shanghai, China). 4-Methylbenzhydrylamine resin HCl salt (rink amide MBHA resin) was from Xi'an Innovision Bioscience Co., Ltd. O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium hexafluorophosphate (HBTU) was purchased from American Bioanalytical Co., Ltd. (Natick, MA, USA). Diisopropylethylamine (DIEA) was supplied by Sigma-Aldrich. 4ʹ,6-Diamidino-2-phenylindole (DAPI) was supplied by Roche (Basel, Switzerland). 5-Carboxyfluorescein (FAM) was purchased from Sigma (St. Louis, MO, USA). Fluorescein-5-maleimide was purchased from FanboBiochemicals (Beijing, China). LysoTracker ® Red DND-99 was from Invitrogen (Grand Island, NY, USA). Matrigel was obtained from BD Biosciences (San Diego, CA, USA). All chemicals were analytic reagent grade.
U87MG glioblastoma cells and HUVECs were obtained from ATCC. All cells were cultured in special Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% fetal bovine serum (FBS, GE Healthcare's HyClone, USA) at 37°C in a 5% CO 2 -humidified atmosphere. 
Synthesis of peptides
GICP (SSQPFWS), D A7R ( D R D P D P D L D W D T D A) and
Competitive inhibition assay
To determine if the addition of free D A7R and GICP would influence the targeting efficiency of D A7R-GICP peptides, a competitive inhibition assay was conducted on U87MG cells. Each peptide was tested for its ability to inhibit the cellular uptake of other fluorescein labeled peptides. U87MG cells were suspended in phosphate-buffered saline (PBS) and pre-incubated with peptide at 4°C for 2 h, rinsed with PBS and further incubated with fluorescein-labeled peptide for 12 h, and then measured by flow cytometer.
Cellular uptake assay
To qualitatively assess the intracellular uptake of GICP, 
Cellular uptake assay with serum pre-incubation
GICP,
D A7R and D A7R-GICP peptides were pre-incubated with 50% rat serum for 1 h, and then incubated with U87 MG cells and HUVECs for 4 h. The other steps were as described in Section 2.4. 
Lysosome colocalization assay
Peptide crossing BTB assay
In order to evaluate the BTB transferability, a HUVECs/U87 coculture model was established as described previously 25 . HUVECs were seeded in the apical chamber of a transwell and U87 cells were seeded into the basolateral chamber at a 1:5 HUVECs/U87 ratio. For quantitative measurement, three days after seeding, 30 μmol/L FAM and fluorescein-labeled GICP, D A7R and D A7R-GICP solution were added in the apical compartment and after 0.5, 1, 1.5, 2, 3 and 4 h of incubation at 37°C, the transport ratio (%) was measured by microplate reader (Power Wave XS, Bio-TEK, USA). In order to better simulate the tumor environment, tumor spheroids were added into the basolateral chamber, 100 μL FAM and fluorescein-labeled GICP, D A7R and D A7R-GICP solution were added into the apical compartment at a concentration of 30 μmol/L in DMEM with 10% FBS. After a 4 h incubation, tumor spheroids were observed via laser scanning confocal microscope and semi-quantification was conducted by Image J software (NIH, MD, USA). 
Statistical analysis
All data are presented as mean 7 SD unless otherwise indicated. Statistically significant differences between the treatment groups was conducted by one-way ANOVA followed by Bonferroni test; a P value o0.05 was considered as significant.
Results and discussion
Characterization and serum stability of peptides
GICP,
D A7R and D A7R-GICP were synthesized via a standard Boc-protected solid phase peptide synthesis strategy. After purification by preparative C18 RP-HPLC, analytical HPLC was used to confirm that purity was greater than 95% for each peptide. The serum stability assay was conducted in 50% rat serum at 37°C to mimic the in vivo environment. As shown in Fig. 1 , heptapeptide GICP containing natural L-amino acids was degraded in less than 4 h; stabilized peptide D A7R showed a great resistant to enzymatic degradation, and, surprisingly, the coupled peptide D A7R-GICP displayed a significant improvement of stability in serum compared with GICP, increasing its stability to greater than 12 h. The data implied that D A7R-GICP may have better tumortargeting ability than GICP as a result of its longer circulating time in blood and the stability may be due to increased steric hindrance.
Competitive inhibition of peptides
In order to determine whether GICP and D A7R each contribute to the process of D A7R-GICP internalization, a competitive inhibition experiment was carried out with U87MG cells. The fluorescein-labeled peptides could be efficiently internalized into U87MG cells. In contrast, after pre-incubation with GICP or 
Cellular uptake of peptides
The cellular uptake efficiency of GICP, D A7R, D A7R-GICP molecules was evaluated with U87MG cells and HUVECs. The qualitative and the quantitative measurement of peptide uptake was conducted via flow cytometry and laser scanning confocal microscopy. The results are shown in Fig. 3 ; all three peptides can be taken up by U87MG cells and HUVECs, while FAM was barely absorbed. Because VAV3 is relatively overexpressed in tumor cells 12 , GICP peptide uptake was higher in U87MG cells than in D A7R ( Fig. 3A and C) , whereas D A7R was taken up more by HUVECs owing to higher expression of its receptor VEGFR and NRP-1 (Fig. 3B and D) . However, the coupled GICP and D A7R peptide showed better tumor and neovasculature targeting ability, which may result from more receptors for D A7R-GICP peptide and its enhanced hydrophobicity caused by the seven amino-acids linker between D A7R and GICP.
Cellular uptake assay with serum pre-incubation
In order to further validate the influence of serum stability on cellular uptake, the three peptides were pre-incubated with 50% rat serum for 1 h and then incubated with U87MG cells to evaluate uptake efficiency. The results shown in Fig. 4 indicate that enhanced enzymatic stability of D A7R-GICP could maintain its uptake efficiency in both U87MG cells and HUVECs. In contrast, uptake of the non-stabilized peptide GICP was severely decreased by enzyme incubation. of peptide accumulating in tumor spheroid was observed using the Z-stack mode of the laser scanning confocal microscope. In contrast to the studies where the peptides were directly incubated with tumor cluster, FAM showed no fluorescence (Fig. 8C ) whereas GICP and D A7R displayed almost the same fluorescent intensity as seen in ex vivo tumor model, which was far less than D A7R-GICP. The images (Fig. 8C-F) were analyzed by Image J software; the data ( A7R-GICP-Cy7 were used as imaging probes and the mice were imaged with an IVIS system at different time points (Fig. 9) . It appeared that D A7R-GICP peptide accumulated to a greater extent in the tumor region than the individual GICP and D A7R peptides, and reached a maximum at 1.5 h (Fig. 9B) . After 2 h, the mice were killed and the organs were harvested for fluorescent semi-quantification (Fig. 9C) . The results indicate that D A7R-GICP peptide could undergo significant accumulation in the tumors.
Peptide colocalization with lysosomes
Conclusions
In summary, because of the different distributions of the VAV3, VEGFR2 and NRP-1 receptors in U87MG cells and HUVECs, the 
